These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 16220336

  • 1. Effect of a novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats.
    Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT.
    Psychopharmacology (Berl); 2006 Mar; 184(3-4):426-34. PubMed ID: 16220336
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens.
    Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT.
    Neuropharmacology; 2007 Mar; 52(3):755-63. PubMed ID: 17097117
    [Abstract] [Full Text] [Related]

  • 4. The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slices.
    Smith AM, Dhawan GK, Zhang Z, Siripurapu KB, Crooks PA, Dwoskin LP.
    Biochem Pharmacol; 2009 Oct 01; 78(7):889-97. PubMed ID: 19631612
    [Abstract] [Full Text] [Related]

  • 5. N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity.
    Dwoskin LP, Wooters TE, Sumithran SP, Siripurapu KB, Joyce BM, Lockman PR, Manda VK, Ayers JT, Zhang Z, Deaciuc AG, McIntosh JM, Crooks PA, Bardo MT.
    J Pharmacol Exp Ther; 2008 Aug 01; 326(2):563-76. PubMed ID: 18460644
    [Abstract] [Full Text] [Related]

  • 6. bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.
    Wooters TE, Smith AM, Pivavarchyk M, Siripurapu KB, McIntosh JM, Zhang Z, Crooks PA, Bardo MT, Dwoskin LP.
    Br J Pharmacol; 2011 May 01; 163(2):346-57. PubMed ID: 21232049
    [Abstract] [Full Text] [Related]

  • 7. The novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens.
    Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT.
    Eur J Pharmacol; 2008 Dec 28; 601(1-3):103-5. PubMed ID: 19000671
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD).
    Dwoskin LP, Joyce BM, Zheng G, Neugebauer NM, Manda VK, Lockman P, Papke RL, Bardo MT, Crooks PA.
    Biochem Pharmacol; 2007 Oct 15; 74(8):1271-82. PubMed ID: 17727820
    [Abstract] [Full Text] [Related]

  • 10. Nicotine and cocaine self-administration using a multiple schedule of intravenous drug and sucrose reinforcement in rats.
    Stairs DJ, Neugebauer NM, Bardo MT.
    Behav Pharmacol; 2010 May 15; 21(3):182-93. PubMed ID: 20440201
    [Abstract] [Full Text] [Related]

  • 11. Reboxetine: attenuation of intravenous nicotine self-administration in rats.
    Rauhut AS, Mullins SN, Dwoskin LP, Bardo MT.
    J Pharmacol Exp Ther; 2002 Nov 15; 303(2):664-72. PubMed ID: 12388649
    [Abstract] [Full Text] [Related]

  • 12. Role of α4- and α6-containing nicotinic receptors in the acquisition and maintenance of nicotine self-administration.
    Madsen HB, Koghar HS, Pooters T, Massalas JS, Drago J, Lawrence AJ.
    Addict Biol; 2015 May 15; 20(3):500-12. PubMed ID: 24750355
    [Abstract] [Full Text] [Related]

  • 13. Reinforcement enhancing effect of nicotine and its attenuation by nicotinic antagonists in rats.
    Liu X, Palmatier MI, Caggiula AR, Donny EC, Sved AF.
    Psychopharmacology (Berl); 2007 Nov 15; 194(4):463-73. PubMed ID: 17616849
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mecamylamine attenuates cue-induced reinstatement of nicotine-seeking behavior in rats.
    Liu X, Caggiula AR, Yee SK, Nobuta H, Sved AF, Pechnick RN, Poland RE.
    Neuropsychopharmacology; 2007 Mar 15; 32(3):710-8. PubMed ID: 16794568
    [Abstract] [Full Text] [Related]

  • 17. Intravenous nicotine self-administration in rats: effects of mecamylamine, hexamethonium and naloxone.
    DeNoble VJ, Mele PC.
    Psychopharmacology (Berl); 2006 Mar 15; 184(3-4):266-72. PubMed ID: 16088413
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat.
    Albayati ZA, Dwoskin LP, Crooks PA.
    Drug Metab Dispos; 2008 Oct 15; 36(10):2024-9. PubMed ID: 18617603
    [Abstract] [Full Text] [Related]

  • 19. Mecamylamine, dihydro-beta-erythroidine, and dextromethorphan block conditioned responding evoked by the conditional stimulus effects of nicotine.
    Struthers AM, Wilkinson JL, Dwoskin LP, Crooks PA, Bevins RA.
    Pharmacol Biochem Behav; 2009 Dec 15; 94(2):319-28. PubMed ID: 19778551
    [Abstract] [Full Text] [Related]

  • 20. Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents.
    Dwoskin LP, Sumithran SP, Zhu J, Deaciuc AG, Ayers JT, Crooks PA.
    Bioorg Med Chem Lett; 2004 Apr 19; 14(8):1863-7. PubMed ID: 15050617
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.